Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-08-06 Regulatory Filings
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin regarding the launch of a new CE marked diagnostic test (LIAISON® Testosterone xt test). The structure includes a subject line, date, company details, and a body describing the product launch and its significance. The key indicator is the 'Oggetto' (Subject) which states 'DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test...'. This is a specific business update related to product commercialization, not a general financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). Since it is a specific announcement about a new product launch and commercial activity, it fits best under the general 'Regulatory Filings' (RNS) category as a specific business update that doesn't match the other specialized codes, although it is a product announcement. Given the options, RNS serves as the best fit for a specific, non-financial, non-governance regulatory announcement that is not covered by other codes like ER or CT. However, upon reviewing the definitions, this is a specific business development announcement. Since there is no specific code for 'Product Launch' or 'Commercial Update', RNS (Regulatory Filings / miscellaneous announcements) is the appropriate fallback.
2020-08-06 English
DiaSorin lancia il test LIAISON Testosterone xt con marcatura CE per il dosaggio del testosterone
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin, identified by the header 'Informazione Regolamentata n. 0957-71-2020' and the 'Oggetto' (Subject) describing the launch of a new CE-marked diagnostic test (LIAISON® Testosterone xt). The text is short (under 5,000 characters) and explicitly states 'Vedi allegato' (See attachment) and provides contact information for Investor Relations. This structure—a brief announcement about a new development or publication, often referencing an attachment or further details—strongly suggests a general regulatory disclosure rather than the full report itself. Since it is a specific announcement about a product launch/development that doesn't fit into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing fallback category, RNS (Regulatory Filings). It is not an Earnings Release (ER) or a Call Transcript (CT).
2020-08-06 Italian
Notice availability Half-Year Financial Report
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 2,000 characters) from DiaSorin S.p.A. stating that the 'Half-Year Financial Report at June 30th, 2020' has been approved and is now available for viewing on the company's website and storage mechanisms. Per the 'Menu vs Meal' rule, since this document is an announcement of the availability of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). H1 2020
2020-08-03 English
Avviso disponibilità Relazione Finanziaria Semestrale
Report Publication Announcement Classification · 99% confidence The document is a formal announcement dated August 3, 2020, with the subject line 'Avviso disponibilità Relazione Finanziaria Semestrale' (Notice of availability of the Semi-Annual Financial Report). The text explicitly states that the 'Relazione Finanziaria Semestrale' (Semi-Annual Financial Report) for the period ending June 30, 2020, is available to the public at the registered office, via eMarket STORAGE, and on the company website. Since the document itself is short (2107 chars) and its primary function is to announce the availability of a comprehensive report (the Semi-Annual Financial Report), it fits the definition of a Report Publication Announcement (RPA). The comprehensive report itself would likely be classified as an Interim/Quarterly Report (IR), but this document is the announcement of that report.
2020-08-03 Italian
Relazione Finanziaria Semestrale al 30 giugno 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RELAZIONE FINANZIARIA SEMESTRALE DEL GRUPPO DIASORIN AL 30 GIUGNO 2020' (Half-Year Financial Report of the DiaSorin Group as of June 30, 2020). It contains a comprehensive index, management report, consolidated financial statements (balance sheet, income statement, cash flow), and explanatory notes. It is a full interim financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-03 Italian
Weekly report treasury shares buy-back
Transaction in Own Shares Classification · 98% confidence The document is titled 'REPORT ON THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN S.P.A.' and details the number of ordinary shares purchased, the consideration paid, and the resulting treasury share holding as of July 31st, 2020. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS. Although it is a report, the document structure suggests it is the primary disclosure of the transaction activity, not just an announcement of a report's publication (RPA).
2020-07-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.